Leede Financial Analysts Cut Earnings Estimates for TSE:CPH

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Stock analysts at Leede Financial dropped their FY2025 earnings estimates for shares of Cipher Pharmaceuticals in a note issued to investors on Friday, November 8th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $0.93 for the year, down from their previous forecast of $1.02. Leede Financial has a “Hold” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.14 EPS.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus lifted their target price on shares of Cipher Pharmaceuticals from C$17.00 to C$19.00 in a report on Thursday, October 24th. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th.

Cipher Pharmaceuticals Price Performance

Shares of TSE CPH opened at C$13.88 on Monday. The stock has a market cap of C$355.19 million, a P/E ratio of 11.10 and a beta of 1.20. Cipher Pharmaceuticals has a twelve month low of C$4.40 and a twelve month high of C$19.69. The stock has a 50 day moving average of C$16.19 and a two-hundred day moving average of C$12.27. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing the consensus estimate of C$0.03 by C($0.02). The firm had revenue of C$14.15 million during the quarter, compared to analysts’ expectations of C$13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.